Malene Brondberg
Director/Board Member bei PHOTOCURE ASA
Vermögen: 3 185 $ am 31.03.2024
Profil
Malene Brondberg is currently a Director at Photocure ASA. She was previously the Head of Global Research at ABG Sundal Collier Holding ASA and the Global Head of Research at ABG Sundal Collier ASA. From 2018 to 2023, she served as the Chief Executive and Financial Officer at Nordic Nanovector ASA. Ms. Brondberg holds a graduate degree and an MBA from the University of Aalborg.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
THOR MEDICAL ASA
0,01% | 31.12.2022 | 32 000 ( 0,01% ) | 3 185 $ | 31.03.2024 |
Aktive Positionen von Malene Brondberg
Unternehmen | Position | Beginn |
---|---|---|
PHOTOCURE ASA | Director/Board Member | - |
Ehemalige bekannte Positionen von Malene Brondberg
Unternehmen | Position | Ende |
---|---|---|
THOR MEDICAL | Chief Executive Officer | 01.02.2023 |
ABG Sundal Collier ASA
ABG Sundal Collier ASA Investment Banks/BrokersFinance Part of ABG Sundal Collier Holding ASA, ABG Sundal Collier ASA provides brokerage services. The private company is based in Oslo, Norway. The Norwegian company was founded in 2001. Peter Straume has been the CEO of the company since 2020. | Director of Research - Equity | - |
ABG SUNDAL COLLIER HOLDING ASA | Corporate Officer/Principal | - |
Ausbildung von Malene Brondberg
University of Aalborg | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
ABG SUNDAL COLLIER HOLDING ASA | Finance |
PHOTOCURE ASA | Health Technology |
Private Unternehmen | 2 |
---|---|
ABG Sundal Collier ASA
ABG Sundal Collier ASA Investment Banks/BrokersFinance Part of ABG Sundal Collier Holding ASA, ABG Sundal Collier ASA provides brokerage services. The private company is based in Oslo, Norway. The Norwegian company was founded in 2001. Peter Straume has been the CEO of the company since 2020. | Finance |
Nordic Nanovector ASA
Nordic Nanovector ASA Pharmaceuticals: MajorHealth Technology Nordic Nanovector ASA is a biopharmaceutical company, which engages in the development, marketing, and sale of medical products and equipment for anticancer therapeutics for haematological cancers. The firm offers the Betalutin which is an antibody radionuclide conjugates for the treatment of non-Hodgkin lymphoma. It operates through the following geographical segments: Norway, Switzerland, and the United Kingdom. The company was founded by Roy Hartvig Larsen, Oyvind Sverre Bruland, and Jostein Dahle on July 2, 2009 and is headquartered in Oslo, Norway. | Health Technology |